An interventional study of Written exercise guidance by neurologist and Physical therapy in Parkinson Disease, sponsored by Shirley Ryan AbilityLab. Enrolling by invitation at 7 sites in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Shirley Ryan AbilityLab · Not applicable, Interventional, and Treatment
Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 117th largest by planned enrollment of the 1,256 interventional ones that give a count, is one of 81 that started in 2024, is one of 585 with no phase, reaches primary completion later than 270 of the 384 other live ones, and was the 1,399th registered.
4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, United Kingdom
Ages 40–85
Medical University of South Carolina · Sites in United States
Ages 50–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 63 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,649 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 81 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 288 is above the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,256 interventional studies, 78 across the 379 observational. Of the 1,139 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,649 have an industry lead sponsor. The 10 most frequent:
Shirley Ryan AbilityLab is the lead sponsor of 180 studies on the registry; 44 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
Shirley Ryan AbilityLab has 8 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
139 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT05558189Stanford UniversityVibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients | 2026-11-21 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
Among the 1,649 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about exercise and physical activity people with Parkinson's Disease. The main questions it aims to answer are: 1) learn about the physical activity and exercise behaviors of people with Parkinson's Disease over the course of a year and 2) compare 3 exercise guidance strategies aimed to impact exercise behavior: standard care, written exercise guidance from neurologist and/or physical therapy.
During the course of the study:
The purpose of this study is to gain a better understanding of how people with Parkinson's disease (PD) manage their physical activity and exercise participation with different levels of support from their communities and clinicians. We will evaluate exercise and physical activity every 3 months in a cohort of people with PD from two medical centers in the Chicagoland area: Northwestern Medicine and University of Chicago Medical Center.
During this study, we will evaluate differences in 12-month physical activity trajectories between groups enrolled during each of three conditions: (1A) standard care (condition 1, year 1), (1B) written exercise guidance (condition 2, year 2), and (1C) Consultative PT (condition 3, year 3). People with PD will be enrolled each year into an activity and exercise tracking study. Participants will be tracked using a remote therapeutic monitoring platform (Datos) and commercial grade activity trackers. Research-grade actigraphy and patient reported outcome measures will be monitored every 3 months for the first year.
All participants will be enrolled in an exercise and physical activity tracking study where they can use a remote therapeutic monitoring platform (Datos Health) to share their exercise and physical activity data with their medical and rehabilitation teams at NM and UCMC. The platform allows for synchronization of patients' activity data from their fitness tracker or smartwatch to the secure cloud-based platform. The platform can summarize steps per day, activity intensity, minutes of moderate-vigorous physical activity per day based on target heart rate zones (including an ability for physical therapists to customize the target heart rate zone).
At the 2 sites of care (Northwestern Medicine and University of Chicago), participants will be recruited based on contacting consecutive patients who meet the inclusion criteria based on scheduling and EMR screening prior to their visit with their neurologists. Contacting consecutive patients will ensure greater potential equity of enrolling participants rather than only patients engaged in support groups and exercise classes. However, after 3 months of recruitment, we will conduct a preliminary analysis of the numbers, recruitment rates, and characteristics (age, sex, race, ethnicity, disease duration, education) of the enrolling participants compared to the demographics of each clinic as a whole. We will then determine if we should use targeted recruitment strategies to increase reach to specific groups or recruitment rates by doing one or more of the following: (1) sending measures through MyChart to potentially eligible patients targeting or oversampling for higher socioeconomic, race, or ethnicity diversity or (2) reaching out to local community exercise classes or support groups using emails to community advocates and flyers to increase sample size more rapidly.
Consecutive patients meeting the eligibility criteria will be approached by a site study team member. The first contact may occur before or during a medical (physician, physician assistant, nurse practitioner) visit. The electronic health record system will be used to screen participants for eligibility in the few weeks before their visit through an institutional review board-approved electronic data warehouse data waiver. Attempts will be made to contact potential participants before their appointments, with a research coordinator attempting contact at their visit if there is no response to early contacts. If time is limited during the patient's session, we will use patient portal communication and/or phone calls after their visits depending on the preferences of each site (which will be determined during the pre-implementation barrier assessment).
Screening for eligibility will occur via a combination of data available in the EMR for existing patients and a quick screening questionnaire that can be done in person or over the phone. After identifying that the participant is interested and satisfies the inclusion criteria for the study, they will be sent an e-consent. Once consent is obtained, they will work with the study team to set a time for the baseline assessment period which will include ensuring the participant has their own -wrist-worn activity tracker and is able to get commercial grade activity tracker from the research team. At baseline and every 3-months throughout the 12-month (baseline, 3-months, 6-months, 9-months, 12-months) study, participants will complete online survey assessments including demographic questionnaires, habits and perceptions of physical activity and exercise, and healthcare and exercise resource utilization. Participants will, also, wear a research-grade physical activity monitor on a belt clip around their waist for 7-consecutive days at baseline, 3-, 6-, 9-, 12-months. In addition to research-grade physical activity monitoring, participants will be asked to asked to a personal commercially available activity tracker daily which will be synced to the Datos Health app.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard care patient's with Parkinson's Disease are receiving at each site.
Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease.
Other: Written exercise guidance by neurologist
A consultative model of physical therapy will be implemented at each site for patient's with Parkinson's Disease.
Other: Physical therapy
Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease during neurologist visits and/or in after visit summary in the patient's EMR patient portal. The research team will facilitate the development of the written exercise guidance with input and feedback from each site's neurology, clinical, and administrative teams.
A consultative model of physical therapy - a lower dose of physical therapy focused on physical activity and exercise promotion and coaching - will be implemented into each site. In the consultative model of physical therapy, visits are scheduled around needs of the patient, however will involve 1-4 additional visits within 3 months of evaluation and is based on personal factors that influence their exercise prognosis such as self-efficacy, readiness to change, fitness level, age, health literacy, comorbidities, and Parkinson's Disease-related motor and non-motor impairments.
Accelerometer Measures
Minutes per day of moderate to vigorous physical activity (MVPA)
Time frame: Average 1-week MVPA measured every 3-months throughout 12-month study period
Steps per Day
Steps per day
Time frame: Average 1-week step counts measured every 3-months throughout 12-month study period
Plan to share: Yes — In accordance with the "NICHD Plans for Sharing Human and Non-Human Data and/or Biospecimens" policy, resulting data will be shared in the Data and Specimen Hub (DASH) in de-identified format. Our research results will also be made available to the public via summaries on the Shirley Ryan AbilityLab (SRAlab) website and Northwestern University's DigitalHub, a repository for scholarly output through Northwestern University developed by Galter Health Sciences Library (Northwestern).
Supporting information: Statistical analysis plan
Time frame: Data will become available following completion and analysis of research study data. Data will be stored in our laboratory data repository system and thus will be available indefinitely.
Access criteria: Data summaries will be publicly available on the Shirley Ryan AbilityLab website and Northwestern University DigitalHub. De-identified data will, also, be shared in the Data and Specimen Hub (DASH) through the NICHD.
Started Mar 2024 (actual). Primary completion is estimated for May 2028, 50 months after the start.
Of 1,291 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 50 months is above that.
Counting every sponsor, half of 1,367 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.